An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

351

Participants

Timeline

Start Date

October 11, 2012

Primary Completion Date

July 1, 2016

Study Completion Date

July 1, 2016

Conditions
Colorectal Cancer
Interventions
DRUG

Bevacizumab

Bevacizumab will be administered as per approved label.

DRUG

Chemotherapy

The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.

Trial Locations (9)

114

Tri-Service General Hospital; Hematology and Oncology, Taipei

333

Chang Gung Medical Foundation - Linkou; Colo-rectal Surgery, Taoyuan District

407

Taichung Veterans General Hospital; Dept of Surgery, Taichung

613

Chang Gung Medical Foundation - Chai Yi; Surgery, CHAI YI

704

National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan City

807

Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung City

00833

Kaohsiung Chang Gung Memorial Hospital; Colorectal Surgery, Kaohsiung City

00112

Veterans General Hospital; Division of Oncology, Taipei

Unknown

Mackay Memorial Hospital; Department of Surgery, Division of Colon and Rectal Surgery, Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01712347 - An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter